Sangamo claims a major milestone in gene editing, treating first patient with its zinc finger nuclease tech
While the leading CRISPR biotechs have been focused on a long, slow windup to their first human studies, one of the original players in the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
